BIIB34:BVMF
Biogen
188,28 BRL
0,00%
(0,00) 1D
21. ruj, 16:31:47 GMT -3 · BRL
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za BIIB34...
Trž. kap.
32,92 mlr.
Prosj. kol.
6,00
Količina
0,00
52-tjed. najviša
191,00 BRL
52-tjed. najniža
128,69 BRL
Dionice u optjecaju
147,75 mil.
Broj djelatnika
8 tis.
Trž. kap.
32,92 mlr.
Prosj. kol.
6,00
Količina
0,00
52-tjed. najviša
191,00 BRL
52-tjed. najniža
128,69 BRL
Dionice u optjecaju
147,75 mil.
Broj djelatnika
8 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
Yahoo Finance
·
prije 3 dana
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
Profil
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Biogen – informacije
Glavni izvršni direktorChris Viehbacher
Zaposlenici7,5 tis.
Osnovano1978
SjedišteCambridge, Massachusetts, Sjedinjene Američke Države
Sektor-
Web-lokacijabiogen.com